Full-Time

Research Associate II

Posted on 8/26/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$94k - $114kAnnually

Junior, Mid

San Bruno, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Requirements
  • BS/MS in Biology, Physiology, Pharmacology, or a related field with 2+ years of relevant research experience
  • Proficiency in basic rodent handling and dosing techniques is required
  • Basic data management skills and the ability to present data clearly and effectively
  • Excellent oral and written communication skills are essential
Responsibilities
  • Conduct and manage in vivo experiments assessing the efficacy of small molecule compounds related to cardiac diseases
  • Oversee animal colony cohorts for in vivo studies, ensuring adherence to ethical guidelines and protocols
  • Measure biomarkers of disease progression and compound efficacy
  • Collaborate closely with team members to identify, characterize, and progress compounds through preclinical research stages
  • Document experimental results, manage data, prepare and present summary presentations to project teams

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments indicate strong interest in muscle activators and inhibitors.
  • Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
  • Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

What critics are saying

  • Increased competition could impact market share and profitability.
  • Potential delays in clinical trials could hinder drug commercialization.
  • Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE